Four thousand UK volunteers needed for latest COVID-19 vaccine study Published:
4,000 volunteers are set to be recruited to the latest vaccine study running in the UK, examining a new COVID-19 vaccine candidate.
Developed by specialty vaccine company Valneva, the vaccine is being manufactured at the company’s site in Livingston, West Lothian. It is the only inactivated, adjuvanted (an ingredient to create a strong immune response) COVID-19 vaccine in clinical development in Europe.
The study will be running across 22 National Institute for Health Research (NIHR) sites in England, and two sites in Scotland, and is open to healthy adults who have not had a previous COVID-19 vaccine.
NIH funds large Phase 3 clinical trial to test repurposed drugs for treating COVID-19 symptoms
Using an ACTIV master protocol, the trial will focus on potential interventions for mild-to-moderate illness.
The National Institutes of Health will fund a large, randomized, placebo controlled Phase 3 clinical trial to test several existing prescription and over-the-counter medications for people to self-administer to treat symptoms of COVID-19. Part of the Accelerating COVID 19 Therapeutic Interventions and Vaccines (ACTIV) public-private partnership, the ACTIV-6 trial aims to provide evidence-based treatment options for the majority of adult patients with COVID-19 who have mild-to-moderate symptoms and are not sick enough to be hospitalized. NIH will provide an initial investment of $155 million in funding for the trial.
Using an ACTIV master protocol, the trial will focus on potential interventions for mild-to-moderate illness.
The National Institutes of Health will fund a large, randomized, placebo‑controlled Phase 3 clinical trial to test several existing prescription and over-the-counter medications for people to self-administer to treat symptoms of COVID-19. Part of the Accelerating COVID‑19 Therapeutic Interventions and Vaccines (ACTIV) public–private partnership, the ACTIV-6 trial aims to provide evidence-based treatment options for the majority of adult patients with COVID-19 who have mild-to-moderate symptoms and are not sick enough to be hospitalized. NIH will provide an initial investment of $155 million in funding for the trial.
Large clinical trial to study repurposed drugs to treat COVID-19 symptoms miragenews.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from miragenews.com Daily Mail and Mail on Sunday newspapers.
Sam Lisco
It’s true that we learn from our mistakes, but given the choice, wouldn’t we all prefer to learn from the mistakes –
and the achievements – of others.
Samantha Liscio, 2020 Canadian CIO of the Year (public sector), makes a powerful case for vicarious learning as a guest on ITWC’s podcast series,
Series host, ITWC CIO Jim Love, opens the 45-minute podcast with an introduction to Liscio, former Chief Technology and Innovation Officer for Ontario’s Workplace Safety and Insurance Board, and incoming Chief Information and Technology Officer for the UK’s National Institute for Health Research (NIHR) Clinical Research Network (CRN). A digital transformation specialist with 20 years of experience in IT leadership roles, she comes to the table with a deep love of technology and a personal playbook for success.